Sanofi scraps rare-disease drug deal under FTC pressure


The day is beginning with clear blue skies and sunshine at the Pharmalot campus. The company’s newest mascot is enjoying the outdoors in search of creatures, and Pharmalot is busy as ever hunting for items of interest. According to CNBC, Eli Lilly’s weight loss drug, Zepbound, is causing patients to regain about half of the shed weight after discontinuing the treatment for a year. A study shows that people have to continue the weekly injection for maintaining significant weight loss. Additionally, some patients with type 2 diabetes are encountering issues with getting reimbursed for diabetes drugs like Ozempic, as U.S. insurers are imposing new restrictions.

Source link

error: Content is protected !!